Neuroprotective effect of sulforaphane against methylglyoxal cytotoxicity.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study in a cell line; mechanism-based bench research without human subjects.
PubMed 25933243 · doi:10.1021/acs.chemrestox.5b00067
What was done
Researchers evaluated the protective effects of sulforaphane against methylglyoxal-induced cytotoxicity in cultured human SH-SY5Y neuroblastoma cells. Assayed outcomes included caspase-3 activation, MAPK phosphorylation (ERK1/2, JNK, p38), oxidative stress levels, intracellular glutathione, glyoxalase 1 expression and enzymatic activity, brain-derived neurotrophic factor (BDNF) pathway modulation, and cellular glucose uptake.
What was found
The abstract provides no quantitative values, specific concentrations, or effect sizes. Qualitatively, sulforaphane inhibited caspase-3 activation, reduced MAPK pathway phosphorylation, diminished oxidative stress, and raised intracellular glutathione. It also upregulated the expression and enzymatic activity of glyoxalase 1, modulated BDNF signaling, and restored glucose uptake that had been impaired by methylglyoxal exposure.
Why it matters
This study outlines multiple cellular mechanisms through which sulforaphane can mitigate dicarbonyl stress and advanced glycation end-product precursors in neuronal cell models.
Limits
The study is restricted entirely to an in vitro immortalized cell line (SH-SY5Y) and cannot account for in vivo pharmacokinetics, blood-brain barrier permeability, or metabolism. No quantitative data, dose ranges, or statistical measures are reported in the abstract.
Cited by
- supports Methylglyoxal is a precursor to advanced glycation end products (AGEs) associated with Alzheimer's disease.